Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis

JAMA

Volumn 301, Issue 2, 2009, Pages 198-209

  Häuser, Winfried ^a   Bernardy, Kathrin ^b,c   Üçeyler, Nurcan ^d   Sommer, Claudia ^d  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Department of Psychosomatic Medicine   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; MILNACIPRAN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PARACETAMOL; PIRLINDOLE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; FIBROMYALGIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ANTIDEPRESSIVE AGENTS; FIBROMYALGIA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 58249090925     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.944     Document Type: Review

References (69)

1. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17(4):547-561.
2. Wolfe F, Smythe HA, Yunus MB, et al; Report of the Multicenter Criteria Committee. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum. 1990;33(2):160-172.
3. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
4. Häuser W, Zimmer C, Felde E, Kollner V. What are the key symptoms of fibromyalgia? results of a survey of the German Fibromyalgia Association [in German]. Schmerz. 2008;22(2):176-183.
5. Wolfe F, Anderson J, Harkness D, et al. Work and disability status of persons with fibromyalgia. J Rheumatol. 1997;24(6):1171-1178.
6. Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis. 2005;64(3):396-402.
7. Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31(7):1391-1398.
8. Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil. 2005;27(12):685-694.
9. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7(8):1027-1039.
10. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet. 2007;369(9565):946-955.
11. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388-2395.
12. Carville SF, Arendt-Nielsen S, Bliddal H, et al; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536-541.
13. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15(9):659-666.
14. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics. 2000;41(2):104-113.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896-1900.
16. Bero L, Rennie D. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995;274(24):1935-1938.
17. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31(1):150-153.
18. Smythe HA, Moldofsky H. Two contributions to understanding of the 'fibrositis' syndrome. Bull Rheum Dis. 1977;28(1):928-931.
19. Yunus MB. Primary fibromyalgia syndrome: a critical evaluation of recent criteria developments. Z Rheumatol. 1989;48(5):217-222.
20. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952-960.
21. van Tulder M, Furlan A, Bombardier C, Bouter L; Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine. 2003;28(12):1290-1299.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
23. Review Manager (RevMan) version 4.2.10 [computer program]. The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
24. Altman DG, Bland JM. Standard deviations and standard errors. BMJ. 2005;331(7521):903.
25. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, OK: Lawrence Erlbaum Assoc; 1988.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
27. Orwin RG. A fail-safe N for effect size in meta-analysis. J Stat Educat. 1983;8:157-159.
28. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull. 1979;86:638-641.
29. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235-243.
30. Bibolotti E, Borghi C, Pasculli E. The management of fibrositis: a double-blind comparison of maprotiline (Ludiomil) and placebo. Clin Trials J. 1986;23:269-280.
31. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975-1985.
32. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol. 1991;18(3):447-451.
33. Cantini F, Bellandi F, Niccoli L, Di Munno O. Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia [in Italian]. Minerva Med. 1994;85(3):97-100.
34. Isomeri R, Mikkelsson M, Latikka P, Kammonen K. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. J Musculoskel Pain. 1993;1:253-260.
35. Fors EA, Sexton H, Gotestam KG. The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. J Psychiatr Res. 2002;36(3):179-187.
36. Gonzalez-Viejo MA, Avellanet M, Hernandez-Morcuende MI. A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment [in French]. Ann Readapt Med Phys. 2005;48(8):610-615.
37. Gür A, Karakoç M, Nas K, Çevik R, Saraç J, Ataoǧlu S. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int. 2002;22(5):188-193.
38. Sencan S, Aki S, Karan A, Müslümanoglu L, Ozcan E, Berker E. A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome. Back Musculoskeletal Rehabil. 2004;17(2):57-61.
39. Targino RA, Imamura M, Kaziyama HH, et al. A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. J Rehabil Med. 2008;40(7):582-588.
40. Ozerbil O, Okudan N, Gökbel H, Levendoǧlu F. Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol. 2006;25(4):495-497.
41. Ataoǧlu S, Ataoǧlu A, Erdoǧan F, Saraç J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci. 1997;27:535-539.
42. Çapaci K, Hepgüler S. Comparison of the effect of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clin. 2002;14:223-228.
43. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32-40.
44. Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. Cur Ther Res. 1999;60:696-702.
45. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371-1377.
46. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl. 1989;19:98-103.
47. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4(1):27-35.
48. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191-197.
49. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984.
50. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
51. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum. 1986;29(5):655-659.
52. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995;38(9):1211-1217.
53. Ginsberg F, Joos E, Geczy J, Bruhwyler J, Vandekerckhove K, Famaey JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskeletal Pain. 1998;6:6-17.
54. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain. 1996;4:37-47.
55. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39(11):1852-1859.
56. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37(12):1279-1286.
57. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia: an analysis of outcome measures. Clin Exp Rheumatol. 2001;19(6):697-702.
58. Nørregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61(3):445-449.
59. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120(5):448-454.
60. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(suppl 1):S27-S35.
61. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23(5):255-259.
62. Yavuzer G, Küçükdeveci A, Arasli T, Elhan A. Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil. 1998;8:35-38.
63. Kempenaers C, Simenon G, Vander Elst M, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology. 1994;30(2-3):66-72.
64. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.
65. Living with fibromyalgia, drugs approved to manage pain. US Food and Drug Administration consumer updates. http://www.fda.gov/consumer/updates/ fibromyalgia062107.html. Accessed December 10, 2008.
66. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
67. Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. Biom J. 2006;48(2):271-285.
68. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113-2126.
69. Uceyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-1298.